1-4 of 4
Martine Allard
Close
Sort by
Journal Articles

Population Pharmacokinetic and Pharmacodynamic Analysis of Navtemadlin in Patients with Relapsed and Refractory (R/R) Myelofibrosis (MF) and Other Myeloid or Solid Tumor Malignancies

Lu Zhang, Bill Poland, Shuang Xu, Martine Allard, Cecile Krejsa, J. Greg Slatter
Journal: Blood
Blood (2023) 142 (Supplement 1): 5755.
https://doi.org/10.1182/blood-2023-174749
Published: 2023
Journal Articles

Effect of Food on MDM2 Inhibitor KRT-232 Pharmacokinetics and Macrophage Inhibitory Cytokine-1 (MIC-1) Response in Healthy Volunteers

Shekman Wong, PhD, Cecile Marie Krejsa, PhD, Dana Lee, PharmD, Anna Harris, Emilie Simard, MSc, Xiaohui Wang, Igor Rubets, PhD, Martine Allard, PharmD, PhD, Terry Podoll, PhD, Terry O'Reilly, MD, J. Greg Slatter, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 7–8.
https://doi.org/10.1182/blood-2020-135985
Published: 2020
Journal Articles

Population Pharmacokinetic Analysis of the MDM2 Inhibitor KRT-232 (formerly AMG 232) in Subjects with Advanced Solid Tumors, Multiple Myeloma or Acute Myeloid Leukemia

Shu Chin Ma, PhD, Russ Wada, PhD, Martine Allard, PhD, Greg Slatter, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5766.
https://doi.org/10.1182/blood-2019-131331
Published: 2019
Journal Articles

Concentration-QTc (C-QTc) Analysis of the MDM2 Inhibitor KRT-232 (formerly AMG 232) in Subjects with Advanced Solid Tumors, Multiple Myeloma, or Acute Myeloid Leukemia

Adekemi Taylor, PhD, Martine Allard, PhD, Cecile Kresja, PhD, Dana Lee, PharmD, Greg Slatter, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5768.
https://doi.org/10.1182/blood-2019-131481
Published: 2019